CADL Valuation

Candel Therapeutics Inc

Add to Watchlist

Advanced Chart

5.960

+0.25(4.378%)1D

Overview
Forecast
Valuation
Earnings

CADL Relative Valuation

CADL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CADL is overvalued; if below, it's undervalued.

Historical Valuation

Candel Therapeutics Inc (CADL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.99. The fair price of Candel Therapeutics Inc (CADL) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.83

Fair

-9.32

Trailing

Forward

-4.47

EV/EBITDA

Candel Therapeutics Inc. (CADL) has a current EV/EBITDA of -4.47. The 5-year average EV/EBITDA is -2.57. The thresholds are as follows: Strongly Undervalued below -8.94, Undervalued between -8.94 and -5.76, Fairly Valued between 0.61 and -5.76, Overvalued between 0.61 and 3.79, and Strongly Overvalued above 3.79. The current Forward EV/EBITDA of -4.47 falls within the Historic Trend Line -Fairly Valued range.

-4.42

EV/EBIT

Candel Therapeutics Inc. (CADL) has a current EV/EBIT of -4.42. The 5-year average EV/EBIT is -2.49. The thresholds are as follows: Strongly Undervalued below -9.71, Undervalued between -9.71 and -6.10, Fairly Valued between 1.12 and -6.10, Overvalued between 1.12 and 4.73, and Strongly Overvalued above 4.73. The current Forward EV/EBIT of -4.42 falls within the Historic Trend Line -Fairly Valued range.

0.00

Candel Therapeutics Inc. (CADL) has a current PS of 0.00. The 5-year average PS is 691.01. The thresholds are as follows: Strongly Undervalued below -1287.63, Undervalued between -1287.63 and -298.31, Fairly Valued between 1680.32 and -298.31, Overvalued between 1680.32 and 2669.64, and Strongly Overvalued above 2669.64. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-5.25

P/OCF

Candel Therapeutics Inc. (CADL) has a current P/OCF of -5.25. The 5-year average P/OCF is -3.74. The thresholds are as follows: Strongly Undervalued below -9.97, Undervalued between -9.97 and -6.85, Fairly Valued between -0.62 and -6.85, Overvalued between -0.62 and 2.49, and Strongly Overvalued above 2.49. The current Forward P/OCF of -5.25 falls within the Historic Trend Line -Fairly Valued range.

-7.23

P/FCF

Candel Therapeutics Inc. (CADL) has a current P/FCF of -7.23. The 5-year average P/FCF is -2.92. The thresholds are as follows: Strongly Undervalued below -8.24, Undervalued between -8.24 and -5.58, Fairly Valued between -0.25 and -5.58, Overvalued between -0.25 and 2.41, and Strongly Overvalued above 2.41. The current Forward P/FCF of -7.23 falls within the Undervalued range.

Candel Therapeutics Inc (CADL) has a current Price-to-Book (P/B) ratio of 3.62. Compared to its 3-year average P/B ratio of 0.56 , the current P/B ratio is approximately 551.43% higher. Relative to its 5-year average P/B ratio of 0.90, the current P/B ratio is about 304.04% higher. Candel Therapeutics Inc (CADL) has a Forward Free Cash Flow (FCF) yield of approximately -9.16%. Compared to its 3-year average FCF yield of -50.36%, the current FCF yield is approximately -81.80% lower. Relative to its 5-year average FCF yield of -41.31% , the current FCF yield is about -77.82% lower.

3.47

P/B

Median3y

0.56

Median5y

0.90

-9.16

FCF Yield

Median3y

-50.36

Median5y

-41.31

Competitors Valuation Multiple

The average P/S ratio for CADL's competitors is 3.33, providing a benchmark for relative valuation. Candel Therapeutics Inc Corp (CADL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CADL.O

Candel Therapeutics Inc

Larimar Therapeutics Inc

Loss

331.23M

ZYBT.O

Zhengye Biotechnology Holding Ltd

DiaMedica Therapeutics Inc

Loss

312.46M

Performance Decomposition

Market capitalization of CADL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CADL in the past 1 year is driven by Unknown.